Metraipolis › archive › dc_dce22019e1c5

Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenic POLE mutation: a case report — Europe PMC PMID:42491054

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42491054
DOI
10.1007/s13691-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-10-31T07:21:34.913Z
SHA-256 of the archived text
1ee025ee903d0569138e64207aa35b339461b06b64972b63f63b322a3c13965e
Stable URL of this page
https://metraipolis.com/documento/dc_dce22019e1c5

How to cite

Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenic POLE mutation: a case report — Europe PMC PMID:42491054 — Europe PMC (en), https://europepmc.org/article/MED/42491054 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dce22019e1c5 (Metraipolis archive dc_dce22019e1c5, sha256 1ee025ee903d0569138e64207aa35b339461b06b64972b63f63b322a3c13965e)
BibTeX
@misc{dcdce22019e1c5,
  title = {Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenic POLE mutation: a case report — Europe PMC PMID:42491054},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42491054},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dce22019e1c5; sha256 1ee025ee903d0569138e64207aa35b339461b06b64972b63f63b322a3c13965e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42491054. Agents can read the archived copy with the MCP tool read_document.